Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Optimizing Peripheral Blood Stem Cells Transplantation Outcome Through Amend Relapse and Graft Failure: A Review of Current Literature Publisher



Mohammadi S1 ; Norooznezhad AH1, 2 ; Mohammadi AM1 ; Nasiri H1 ; Nikbakht M1 ; Saki N3 ; Vaezi M1 ; Alimoghaddam K1 ; Ghavamzadeh A1
Authors

Source: Experimental Hematology and Oncology Published:2017


Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has beenconsidered as a valuable approach in treatment of numerous malignant and none malignant hematologic disorders. However, relapse and poor graft function (PGF) after allo-SCT remain to be controversial issues which may affect the transplantation outcome. Relevant articles were searched in MEDLINE database (2000-2016) using keywords and phrases: donor lymphocyte infusions, allogeneic stem cells transplantation, relapsed hematologic malignancies, booster schedules, cell dose, laboratory monitoring protocols and technical aspects of apheresis. Relapse of disease and PGF could be reduced via noting some main points such as choosing the suitable time and patient for donor lymphocyte infusion (DLI) and also determination of patients who ought to candidate for second allogeneic HSCT or for the use of stem cell boost. DLI and stem cell booster are promising treatment strategies noted in this review. Finally, this paper discusses indications and technical aspects of DLI and stem cell booster in hematological malignancies and emphasizes their therapeutic or pre-emptive potentials. © 2017 The Author(s).
Related Docs
View other Related Docs
1. The Role of Donor Leukocyte Infusions in the Treatment of Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation: A Retrospective Analysis, International Journal of Hematology-Oncology and Stem Cell Research (2018)
2. Graft Failure After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients With Acute Leukemia: Autologous Reconstitution or Second Transplant?, Stem Cell Research and Therapy (2024)
3. Hematopoietic Stem Cell Transplantation and Lymphodepletion for the Treatment of Cancer, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
Experts (# of related papers)
View all Related Experts
Amir Ali Hamidieh (5)
Seyed Asadollah Mousavi (4)
Other Related Docs
4. Trends in Patient Outcome Over the Past Two Decades Following Allogeneic Stem Cell Transplantation for Acute Myeloid Leukaemia: An Alwp/Ebmt Analysis, Journal of Internal Medicine (2019)
5. Phase I Non-Randomized Clinical Trial of Allogeneic Natural Killer Cells Infusion in Acute Myeloid Leukemia Patients, BMC Cancer (2023)
6. Disturbance in the Reconstitution of Distinct T-Cell Subsets and the Incidence of Gvhd Following Allo-Hsct in Pediatric Patients With Non-Malignant Hematological Disorders, Immunology Letters (2023)
7. T Helper 17 and Regulatory T-Cell Profile and Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients With Beta-Thalassemia, Transplant Immunology (2023)
8. Dual in Vivo T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation With Post-Transplant Cyclophosphamide and Anti-Thymocyte Globulin As a Third Salvage Transplant for Leukocyte Adhesion Deficiency With Graft Failure: A Case Report, Frontiers in Immunology (2024)
9. Radiation-Free Reduced-Intensity Hematopoietic Stem Cell Transplantation With in Vivo T-Cell Depletion From Matched Related and Unrelated Donors for Fanconi Anemia: Prognostic Factor Analysis, Experimental Hematology (2022)
10. Advances in Hematopoietic Stem Cell Transplantation in the Asia-Pacific Region: The Second Report From Apbmt 2005–2015, Bone Marrow Transplantation (2019)
11. Outcome of Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation As a Treatment Option in Patients With Severe Aplastic Anemia Between 40 and 50 Years, Hematology/ Oncology and Stem Cell Therapy (2022)
12. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older: A Systematic Review and Meta-Analysis, Transplantation and Cellular Therapy (2025)
13. Special Report: Summary of the Eighth Workshop of the Worldwide Network for Blood and Marrow Transplantation on the Status and Issues Related to Hematopoietic Stem Cell Transplantation in Near-East Countries, Held in Pakistan From September 22 to 23, 2022, Hematology/oncology and stem cell therapy (2024)
14. Outcomes of Haploidentical Peripheral Stem Cell Transplantation With Combination of Post-Transplant Cyclophosphamide (Ptcy) and Anti-Thymocyte Globulin (Atg) Compared to Unrelated Donor Transplantation in Acute Myeloid Leukemia: A Retrospective 10-Year Experience, Leukemia Research (2022)
15. The Effect of Diabetes Mellitus Type2 on Mobilization and Autologous Hematopoietic Stem Cell Transplantation Outcomes, Indian Journal of Hematology and Blood Transfusion (2025)
16. Fludarabine-Based Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in a Pediatric Patient With Bone Marrow Failure Syndrome Type 3, Journal of Pediatric Hematology/Oncology (2022)
17. Pre-Hsct Cardiovascular Evaluation, Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation (2024)
18. The Impact of Delayed Versus Early Administration of Granulocyte Colony-Stimulating Factor Following Autologous Hematopoietic Stem Cell Transplantation on Transplantation Outcome, Frontiers in Oncology (2024)
19. Bridging the Gap Between Bone Marrow Transplantation and Car-T Cell Therapy in Hematological Cancers, Advances in Experimental Medicine and Biology (2025)
20. First Report of Pediatric Hematopoietic Stem Cell Transplantation Activities in the Eastern Mediterranean Region From 1984 to 2011: On Behalf of the Pediatric Cancer Working Committee of the Eastern Mediterranean Blood and Marrow Transplantation Group, Bone Marrow Transplantation (2017)